Delcath Systems, Inc. (NASDAQ: DCTH) is a specialty pharmaceutical and medical device company focused on oncology and, more specifically, the treatment of primary and metastatic liver cancers. The company’s proprietary product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. For more information, visit the company’s website at www.delcath.com.